|21st October 2020||Steve Gorlin||5,000||Open or private purchase||$9.19||$45,950.00|
|15th October 2020||Steve Gorlin||100||Open or private purchase||$10.27||$1,027.00|
|15th October 2020||Steve Gorlin||5,000||Open or private purchase||$10.10||$50,500.00|
|15th October 2020||Steve Gorlin||5,000||Open or private purchase||$10.01||$50,050.00|
|15th October 2020||Steve Gorlin||4,000||Open or private purchase||$10.19||$40,760.00|
|15th October 2020||Steve Gorlin||1,000||Open or private purchase||$10.18||$10,180.00|
|9th October 2020||Steve Gorlin||282||Open or private purchase||$9.61||$2,710.02|
|7th October 2020||Steve Gorlin||4,718||Open or private purchase||$9.42||$44,443.56|
|22nd September 2020||Steve Gorlin||15,000||Open or private purchase||$10.00||$150,000.00|
|19th August 2020||John C Thomas||20,000||Open or private sale||$9.19||$183,800.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
NantKwest, Inc. engages in the development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.